IL317103A - Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof - Google Patents

Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof

Info

Publication number
IL317103A
IL317103A IL317103A IL31710324A IL317103A IL 317103 A IL317103 A IL 317103A IL 317103 A IL317103 A IL 317103A IL 31710324 A IL31710324 A IL 31710324A IL 317103 A IL317103 A IL 317103A
Authority
IL
Israel
Prior art keywords
bcl
met
methods
drug conjugates
inhibitor antibody
Prior art date
Application number
IL317103A
Other languages
Hebrew (he)
Original Assignee
Novartis Ag
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Servier Lab filed Critical Novartis Ag
Publication of IL317103A publication Critical patent/IL317103A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL317103A 2022-05-20 2023-05-19 Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof IL317103A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263344460P 2022-05-20 2022-05-20
PCT/US2023/022959 WO2023225336A1 (en) 2022-05-20 2023-05-19 Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof

Publications (1)

Publication Number Publication Date
IL317103A true IL317103A (en) 2025-01-01

Family

ID=86861809

Family Applications (1)

Application Number Title Priority Date Filing Date
IL317103A IL317103A (en) 2022-05-20 2023-05-19 Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof

Country Status (11)

Country Link
US (1) US20250339547A1 (en)
EP (1) EP4525926A1 (en)
JP (1) JP2025517429A (en)
KR (1) KR20250027282A (en)
CN (1) CN119562832A (en)
AR (1) AR129382A1 (en)
AU (1) AU2023273734A1 (en)
CA (1) CA3256012A1 (en)
IL (1) IL317103A (en)
TW (1) TW202404645A (en)
WO (1) WO2023225336A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202617186A (en) * 2024-06-28 2026-05-01 美商飛爾富來生物公司 Bcl-xl degrader antibody conjugates and uses thereof
WO2026051926A1 (en) * 2024-09-04 2026-03-12 成都科岭源医药技术有限公司 Exatecan mesylate-based antibody-drug conjugate, preparation method therefor and use thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3614866B2 (en) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド Artificial antibody polypeptide
JP2002532415A (en) 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Treatment of arthritis with MEK inhibitors
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
CA2512000C (en) 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
KR100883289B1 (en) 2004-06-11 2009-02-11 니뽄 다바코 산교 가부시키가이샤 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido [2,3-D] pyrimidine derivatives and related compounds for cancer treatment
TR201808537T4 (en) 2004-09-23 2018-07-23 Genentech Inc Cysteine modified antibodies and conjugates.
JP4557003B2 (en) 2005-07-01 2010-10-06 株式会社村田製作所 MULTILAYER CERAMIC SUBSTRATE, MANUFACTURING METHOD THEREOF, AND COMPOSITE GREEN SHEET FOR PRODUCTION OF MULTILAYER CERAMIC SUBSTRATE
PE20110217A1 (en) 2006-08-02 2011-04-01 Novartis Ag DERIVATIVES OF 2-OXO-ETHYL-AMINO-PROPIONAMIDE-PYRROLIDIN-2-IL-SUBSTITUTED AS INHIBITORS OF THE BINDING OF THE PROTEIN Smac TO THE INHIBITOR OF THE PROTEIN OF APOPTOSIS
CA2660546A1 (en) 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
TWI441820B (en) 2007-12-19 2014-06-21 Genentech Inc 5-anilinoimidazopyridines and methods of use
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
KR101685718B1 (en) 2008-12-19 2016-12-12 제넨테크, 인크. Heterocyclic compounds and methods of use
EP2376085B1 (en) 2008-12-19 2014-02-26 Genentech, Inc. Compounds and methods of use
BRPI1015234A2 (en) 2009-06-22 2018-02-20 Medimmune Llc fc regions designed for site specific conjugation.
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
BR112014002353B1 (en) 2011-08-01 2022-09-27 Genentech, Inc USES OF PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND KIT
TWI571466B (en) 2011-10-14 2017-02-21 艾伯維有限公司 Apoptosis-inducing agent for treating cancer and immune and autoimmune diseases
TWI561521B (en) 2011-10-14 2016-12-11 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
FR2986002B1 (en) 2012-01-24 2014-02-21 Servier Lab NOVEL INDOLIZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US20140069822A1 (en) 2012-09-10 2014-03-13 Antec Leyden B.V. Electrochemical reduction of disulfide bonds in proteinaceous substances and electrochemical cell for carrying out such reduction
EA201591465A1 (en) 2013-02-08 2015-12-30 АйАрЭм ЭлЭлСи SPECIFIC PLOTS FOR MODIFICATION OF ANTIBODIES FOR OBTAINING IMMUNOCONJUGATES
NZ710385A (en) 2013-02-19 2016-10-28 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
FR3008975A1 (en) 2013-07-23 2015-01-30 Servier Lab NOVEL PYRROLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DK3063143T3 (en) 2013-11-01 2018-08-20 Novartis Ag Amino heteroaryl benzamides as kinase inhibitors
FR3015483B1 (en) 2013-12-23 2016-01-01 Servier Lab NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
BR112016020065A2 (en) 2014-03-12 2018-02-20 Novartis Ag specific sites to modify antibodies to make immunoconjugates
MA39740A (en) 2014-03-13 2017-01-18 Hoffmann La Roche Methods and compositions for modulating estrogen receptor mutants
MX378108B (en) 2014-09-16 2025-03-10 Servier Lab ANTI-MET ANTIBODIES AND COMPOSITIONS.
JP2018502839A (en) 2014-12-09 2018-02-01 アッヴィ・インコーポレイテッド Bcl-xL inhibitory compound and antibody drug conjugate containing the same
EP3229844B1 (en) 2014-12-09 2020-03-04 AbbVie Inc. Antibody drug conjugates with cell permeable bcl-xl inhibitors
RU2017123942A (en) 2014-12-09 2019-01-11 Эббви Инк. BCL-XL INHIBITING COMPOUNDS WITH LOW CELL PERMEABILITY AND ANTIBODY MEDICINES CONJUGATES INCLUDING THEM
WO2020000307A1 (en) 2018-06-28 2020-01-02 深圳市汇顶科技股份有限公司 Radio-frequency power adjustment method, ble chip, ble device and electronic terminal
AR119494A1 (en) 2019-07-29 2021-12-22 Servier Lab 6,7-DIHYDRO-5H-PYRIDO[2,3-c]PYRIDAZIN-8-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PROAPOPTOTIC AGENTS
AR119493A1 (en) 2019-07-29 2021-12-22 Servier Lab 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PROAPOPTOTIC AGENTS
WO2021058735A1 (en) * 2019-09-26 2021-04-01 Symphogen A/S Cancer treatment with anti-met antibody compositions
CN116761635A (en) * 2020-11-24 2023-09-15 诺华股份有限公司 BCL-XL inhibitor antibody drug conjugates and methods of use

Also Published As

Publication number Publication date
AU2023273734A1 (en) 2024-12-12
EP4525926A1 (en) 2025-03-26
CN119562832A (en) 2025-03-04
WO2023225336A8 (en) 2024-07-18
KR20250027282A (en) 2025-02-25
JP2025517429A (en) 2025-06-05
US20250339547A1 (en) 2025-11-06
AR129382A1 (en) 2024-08-21
TW202404645A (en) 2024-02-01
CA3256012A1 (en) 2023-11-23
WO2023225336A1 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
IL288117A (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
IL304168A (en) B7h4-targeted antibody-drug conjugates and methods of use thereof
AU2022205057A9 (en) B7h4-targeted antibody-drug conjugates and methods of use thereof
IL317101A (en) Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
IL320894A (en) Ceacam5 antibody-drug conjugates and methods of use thereof
IL319484A (en) Antibody-drug conjugates targeting napi2b and methods of use
IL314828A (en) Antibody-drug conjugates and their uses
IL316049A (en) Pharmaceutical compositions of mosunetuzumab and methods of use
IL315862A (en) Angiotensinogen-modulating compositions and methods of use thereof
IL325551A (en) Compositions and methods of using pln-targeting antibody-oligonucleotide conjugates
IL325816A (en) Endoxifen compositions and methods for their use and synthesis
IL319485A (en) Antibody-drug conjugates targeting glypican-3 and methods of use
IL316020A (en) Eribulin-based antibody-drug conjugates and methods of use
HK40123865A (en) Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
IL317102A (en) Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
HK40102834A (en) Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
IL326527A (en) Compound and antibody-drug conjugate containing it
HK40130279A (en) Panras inhibitor antibody-drug conjugates and methods of use thereof
CA3284856A1 (en) Panras inhibitor antibody-drug conjugates and methods of use thereof
IL319205A (en) Tissue factor antibody-drug conjugates and uses thereof
HK40102835A (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
HK40072336A (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
HK40073143A (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
HK40108912A (en) Antibody-drug conjugates and methods of use thereof
HK40102881A (en) B7h4-targeted antibody-drug conjugates and methods of use thereof